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Prevalence of Nasal Carriage of Mupirocin-
Resistant Staphylococcus aureus among
Hospitalized Patients in Thailand
To the Editor—In various parts of the world, mupirocin has
been used as a component of a “search and destroy” strategy
to prevent methicillin-resistant Staphylococcus aureus (MRSA)
infection prior to a surgical procedure.1-3 Increased use of
mupirocin has been associated with an increased prevalence
of mupirocin-resistant MRSA.4,5 In Thailand, there is neither
routine surveillance for nasal carriage of MRSA nor attempts
to eradicate carriage among hospitalized inpatients. Given
that mupirocin and antibiotics can be purchased at outpatient
pharmacies in Thailand without a prescription,6 it is expected
that the prevalence of mupirocin-resistant MRSA nasal car-
riage is high. We performed a point prevalence study to eval-
uate the prevalence of MRSA nasal carriage and to estimate
the proportion of individuals with mupirocin-resistant MRSA
nasal carriage among admitted inpatients at Thammasat Uni-
versity Hospital.
From January 1 to January 7, 2010, we cultured anterior
nares swab specimens to detect MRSA carriage. Consecutive
hospitalized patients who consented to the study participation
on day 1 of hospitalization provided swab samples from both
anterior nares that were then cultured for presence of MRSA.
Information regarding demographics and clinical history of
previous admission and exposure to antibiotics (in both in-
patient and outpatient settings) was collected from each pa-
tient. Detection of MRSA from swab specimens was per-
formed as previously described.4 Samples containing MRSA
isolates from all patients who tested positive for MRSA car-
riage were then subcultured to BBL trypticase soy agar with
5% sheep blood (BD Diagnostics) and incubated at 35C for
24 hours. Colonies isolated from the BBL trypticase soy agar
were then inoculated on a Mueller Hinton II plate, and a
mupirocin Etest (AB Biodisk) strip was applied. After 24
hours of incubation at 35C, the minimum inhibitory con-
centration (MIC) was read. Isolates were classified as sus-
ceptible (MIC, !8 mg/mL), low-level resistant (MIC, 8–256
mg/mL), or high-level resistant (MIC, 512 mg/mL).
During the study period, 250 (86%) of 290 adult patients
who were admitted to all units at Thammasat University Hos-
pital provided consent and were enrolled in the study; 149
(60%) were male, and the median age was 45 years (range,
20–89 years). Nasal carriage of MRSA was detected in 9 pa-
tients (3.6%). Four (44%) of these 9 patients were admitted
to medical units, 3 (33%) were admitted to surgical units,
and 2 (23%) were admitted to an orthopedic unit. All patients
with nasal carriage of MRSA had a history of hospital ad-
mission within the past 12 months. Low-level mupirocin-
resistant MRSA was detected in 2 patients (22%). These 2
patients had a history of skin abrasions and had self-pur-
chased mupirocin and fluoroquinolones from a local phar-
macy within 3 months of admission to the hospital.
Our data suggest that MRSA nasal carriage occurred among
patients who had a history of contact with the Thai health
care system, and that injudicious use of mupirocin in the
community may be associated with carriage of low-level mu-
pirocin-resistant MRSA isolates. The relatively low prevalence
of MRSA nasal carriage (3.6%) among hospitalized patients
in our study suggests that a search and destroy strategy may
not be cost-effective to implement in this middle-income
country, while the relatively high prevalence of mupirocin-
resistant MRSA (22%) among patients with nasal carriage of
MRSA suggests the need to employ an antimicrobial stew-
ardship program at the community level to help limit the
unnecessary use of mupirocin and other antibiotics. Further
studies are needed to evaluate the relationship between the
unnecessary use of mupirocin in the community and the
emergence of mupirocin-resistant MRSA among hospitalized
inpatients and to evaluate the cost-effectiveness of a search
and destroy strategy for MRSA in Thailand.
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Pseudo-outbreak of Pseudomonas putida
Respiratory Infection Caused by
Laboratory Contamination
To the Editor—Pseudomonas putida is a gram-negative, aer-
obic bacterium that is a common inhabitant of soil, plants,
and water. It has been found to cause septicemia in immu-
nocompromised patients,1,2 and nosocomial transmission has
been reported, associated with contaminated heparin or an-
tiseptic solutions.3-5 Nevertheless, its isolation from clinical
specimens is rare, and it is usually considered an environ-
mental contaminant. P. putida has also been reported as a
cause of pseudo-outbreaks in contaminated urine collection
kits and contaminated commercial antifog solutions.6,7 We
now report a pseudo-outbreak of P. putida respiratory infec-
tions, involving 5 patients, caused by an automated spiral
plater.
The infection control unit was notified on October 2, 2009,
of a cluster of P. putida isolations from blind distal bronchial
samples from 3 patients undergoing ventilation in the inten-
sive care unit (ICU). The first positive sample had been re-
corded 5 days before, and the two others the day of notifi-
cation. In each sample, P. putida was isolated among other
bacteria at a significant level (at least 103 cfu/mL). Review of
the previous 3 months of microbiology laboratory records
found 2 other instances of P. putida isolation, one from a
bronchial sample of another ICU patient and the other from
sputum of a patient in the pulmonology department. All
isolates presented an identical antibiotic susceptibility pattern.
During the same period, P. putida was not isolated from other
clinical specimens. A thorough ward-based investigation re-
vealed no epidemiological link to suggest cross-infection be-
tween the patients. In particular, the pulmonology depart-
ment patient had never been hospitalized in the ICU and did
not share any device with the ICU patients. Therefore, the
investigation focused on the microbiology laboratory, where
the 5 samples were processed by the same device (a Whitley
Automated Spiral Plater WASP 2; Don Whitley Scientific)
dedicated to the clinical respiratory samples.
The WASP 2 was used for many years without any problem.
It is a fully automated spiral plater, able to load a sample
with a stylus, inoculate a plate, clean the stylus in a sanitizing
solution (70% alcohol), and finally rinse the stylus with sterile
water loaded from a 110-mL reusable container (Figure 1).
The recommendation of the WASP 2 user manual8 is to ster-
ilize the containers filled with sterile water by autoclaving.
Laboratory procedures for handling specimens and clean-
ing processes were reviewed with laboratory personnel. Asep-
tically collected samples of domestic water, demineralized
rinse water, stylus, sanitizing solution, and each of the 12
reusable containers were obtained for bacterial culture. For
the stylus, a 100-mL aliquot of sterile water was loaded by
the stylus and directly deposited on a plate. For domestic
water, demineralized water, sanitizing solution, and reusable
containers containing 110 mL of sterile water, 100 mL of
liquid were filtered and inoculated on plates. Cultures of all
specimens were obtained using conventional microbiologic
methods. Restriction endonuclease DNA profiles were deter-
mined by pulsed-field gel electrophoresis for all available iso-
lates, using the restriction enzyme SpeI.
There was no change in personnel, microbiological tech-
nique, or culture medium. The review of the procedures with
the microbiology laboratory personnel revealed a change in
the process of reusable-container disinfection a few weeks
before the first case occurred. The autoclave usually used to
sterilize the containers filled with sterile water had broken
down, and an alternate procedure consisting of a chemical
disinfection was performed until the autoclave was repaired.
However, as the written procedure requested a rinse with
sterile water after immersion in a bactericidal solution (DDN
250, Franklab Laboratory) for 60 minutes, the employee re-
sponsible for container disinfection had immersed the con-
